Amphastar Pharmaceuticals AMPH Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $98.09M-38.5% | $159.52M+16.0% | $137.55M+50.5% | $91.39M+44.4% | ||
| $31.65M+12.0% | $28.25M+12.1% | $25.21M+5.8% | $23.82M+7.3% | ||
| $27.28M+11.9% | $24.37M+20.4% | $20.24M+13.3% | $17.86M-4.4% | ||
| $3.36M-44.4% | $6.03M-47.1% | $11.4M— | —— | ||
| -$39K— | —— | -$475K-237% | -$141K+59.5% | ||
| —— | —— | —— | $10.13M— | ||
| —— | $48.8M— | —— | —— | ||
| -$4.56M-107% | $63.56M— | —— | -$736K— | ||
| —— | $10.73M+293% | $2.73M+47.1% | $1.85M— | ||
| $25.05M+1.3% | $24.72M+92.7% | $12.83M+1,245% | $954K-10.9% | ||
| $6.51M+53.5% | $4.24M+13.3% | $3.74M+6.7% | $3.51M+7.3% | ||
| $156.12M-26.8% | $213.39M+16.3% | $183.5M+106% | $89.18M-9.0% | ||
| $34.88M-15.0% | $41.04M+7.5% | $38.17M+58.8% | $24.03M-12.5% | ||
| -$70.33M+43.7% | -$124.93M+80.8% | -$649.12M-1,880% | -$32.78M-14.3% | ||
| $75.59M— | —— | $58.14M+45.7% | $39.91M+38.2% | ||
| —— | —— | —— | —— | ||
| $223K-97.3% | $8.26M-97.4% | $318.66M+17,792% | $1.78M-95.2% | ||
| $687K— | —— | —— | $407K— | ||
| -$67.43M+16.7% | -$80.95M— | —— | -$26.44M+28.6% | ||
| —— | -$190K+32.6% | -$282K-18.0% | -$239K— | ||
| —— | —— | -$11.8M— | —— | ||
| $23.22M-13.4% | $26.81M+52.6% | $17.57M+481% | $3.02M+43.3% | ||
| $22.71M-43.4% | $40.1M-18.2% | $49M+10.3% | $44.44M+449% | ||
| —— | —— | —— | —— | ||
| $25.05M+1.3% | $24.72M+92.7% | $12.83M+1,245% | $954K-10.9% | ||
| $31.65M+12.0% | $28.25M+12.1% | $25.21M+5.8% | $23.82M+7.3% | ||
| -$39K— | —— | -$475K-237% | -$141K+59.5% | ||
| —— | -$6.83M-306% | $3.32M— | —— | ||
| —— | $10.73M+293% | $2.73M+47.1% | $1.85M— | ||
| $6.51M+53.5% | $4.24M+13.3% | $3.74M+6.7% | $3.51M+7.3% | ||
| -$5.61M-49.6% | -$3.75M-4.5% | -$3.59M-13.8% | -$3.15M+1.4% | ||
| $687K— | —— | —— | $407K— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | $10.52M— | —— | ||
| $4.36M+5.9% | $4.12M— | —— | $1.37M-47.5% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $121.23M-29.7% | $172.35M+18.6% | $145.34M+113% | $68.29M-9.2% | ||
| $121.23M-29.7% | $172.35M+18.6% | $145.34M+113% | $68.29M-9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amphastar Pharmaceuticals generate?
- Amphastar Pharmaceuticals (AMPH) generated $168.9M in operating cash flow over the trailing twelve months.
- What is Amphastar Pharmaceuticals's free cash flow?
- After $33.7M of capital expenditures, Amphastar Pharmaceuticals's free cash flow was $135.2M over the trailing twelve months, down 10.0% year over year.
- Where does Amphastar Pharmaceuticals's cash flow data come from?
- Every line is extracted from Amphastar Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
